中医药治疗糖尿病并发尿路感染的研究进展

尿路感染是糖尿病常见的并发症之一.本文通过相关文献检索,从糖尿病并发尿路感染的发病机理、发病特征、治疗原则,中、西医的治疗方法等几个方面进行综述,着重从中药的单方验方、中成药、中西医结合治疗等方面阐明中医药在治疗糖尿病并发尿路感染上的优势,不仅疗效显著,还能克服西医治疗产生的耐药性,提高患者免疫力,具有广阔的发展前景.     

中药在TGF-β信号通路抑制肺纤维化中的 作用研究进展

肺纤维化是一种严重致死性疾病,其发病并非单一机制。上皮间质转化（EMT）是肺纤维化发生和发展的重要过程,在这个过程中TGF-β信号通路是其发展的重要机制。TGF-β信号通路分为Smads通路和non-Smads通路。目前中药在治疗肺纤维化方面具有显著作用已被证实,有关其治疗肺纤维化的机制也有大量研究。本文对中药在TGF-β信号通路中的抑制作用作一综述,以期为中药治疗肺纤维化的开发和利用提供参考。     

上皮-间质转化在肺纤维化中的研究进展

肺纤维化是众多肺部疾病的最终表现结果,其形成过程十分复杂,发生的机制也尚未完全阐明。目前的研究发现,上皮-间质转化（epithelial-mesenchymal transition,EMT）是肺纤维化发病机制中的一个关键步骤。转化生长因子-β、Notch和Wingless-type信号通路是普遍认可的介导调控EMT的信号通路。微小核糖核酸及内质网应激等在EMT过程中发挥重要作用。充分认识EMT在肺纤维化发生发展中的作用,有助于寻找治疗肺纤维化的新方法和新药物。本文就近年来国内外学者对EMT在肺纤维化中的研究新进展进行综述。     

特发性肺纤维化的组学研究进展

特发性肺纤维化(IPF)是一种原因不明的以呼吸困难和肺功能进行性恶化为特征的慢性肺纤维化性疾病,预后不良。IPF的病因尚未完全阐明,与老化、遗传、环境暴露、氧化应激和微生物-宿主防御反应有关。基因突变、转录和翻译异常、表观基因调控改变及代谢紊乱均可能影响疾病的发生和发展。近年来,采用高通量技术的组学研究从多维度揭示了IPF的发病机制,为寻找生物标志物和治疗靶点提供了新视角。本文综述了应用基因组学、转录组学、表观基因组学、蛋白质组学和代谢组学技术阐明IPF发病机制、寻找生物标志物、提供治疗靶点的最新研究进展。     

自噬调节与特发性肺纤维化药物治疗研究进展

特发性肺纤维化（idiopathic pulmonary fibrosis，IPF）是一种病因复杂、与年龄相关的肺纤维化疾病，其发病过程表现出进行性与不可逆性，最终导致患者呼吸系统衰竭而死亡。近些年的研究证实自噬参与了IPF的发生发展。本文回顾总结了自噬和IPF相关的临床研究、动物和细胞模型研究以及基于自噬的药物治疗研究，希望对阐明IPF的病理机制和药物研发有所帮助。     

代谢组学在中药治疗肾脏疾病及中药毒性研究的应用与进展北大核心CSCD

随着代谢组学不断发展,其在中药领域的应用越来越广泛。基于代谢组学在中药领域的应用,本文综述了中药治疗肾脏疾病及中药毒性研究文献,为阐明中药治疗肾脏病的生物化学作用机理及中药毒性机制,发掘治疗肾脏病新药物及提高用药安全性等提供参考。     

特发性肺纤维化抗体药物研发进展

特发性肺纤维化是一种纤维化疾病。目前其发病机制尚未被完全阐明,而且没有确切治疗效果的药物用于此疾病。抗体药物经过4个阶段的发展,以其自身优势正成为药物研发的新热点。目前,已有多款药物进入临床试验研究阶段。基于此,本文总结了针对特发性肺纤维化临床试验研究阶段的抗体药物,以期对抗体药物的发展进行总结,为抗体药物的研发提供一定的依据与思路。     

从指南看特发性肺纤维化治疗药物的选择

自1892年首次报道慢性间质性肺病的组织病理学以来,相关研究不断深入,其中特发性肺纤维化(IPF)发病机制的研究也取得了一定进展,但仅个别药物可能对IPF具有潜在益处.依据2011年《特发性肺纤维化诊治循证指南》,本文简要综述指南提出的4种IPF药物治疗方案的研究现状.     

近年来中药抗过敏反应研究的概况

<正> 近年来随着免疫学研究的进展,中药抗过敏反应的研究已愈来愈受到重视,并发现多种单味和复方中药及其提取物或成分具有抗过敏反应作用,临床用于防治过敏性疾病也取得较好疗效,且无严重的副作用。本文重点简述以抗Ⅰ型变态反应为主的中药,并依中药制剂,中药提取物或单体物质等归纳论述。 过敏反应及其引起的病症多属Ⅰ型变态反应,其发病机理是变应原进入机体后,刺     

特发性肺纤维化的研究进展及其治疗

特发性肺纤维化(IPF)是一种进行性加重且目前尚无有效治疗药物的疾病,相关病因尚未明确.近期研究发现了IPF新的治疗靶点.本文综述IPF的发病机制、诊断的最新研究,以及其治疗的研究进展.     

黄芪丹参茯苓龟板合剂对大鼠肾间质纤维化的抑制作用

目的 探讨黄芪丹参茯苓龟板合剂对肾间质纤维化进展过程的干预作用及其机制.方法 通过单侧输尿管梗阻法建立肾间质纤维化的大鼠模型,实验分为假手术(Sham) 组、单侧输尿管梗阻 (UUO) 组、血管紧张素转换酶抑制剂(ACEI) 组及黄芪丹参茯苓龟板合剂(中药)组,术后第14天取大鼠肾组织进行常规HE、Masson染色及C...     

单味中药防治脂肪肝作用的研究进展

脂肪肝发病率已跃居为肝病第一位，中药治疗脂肪肝有显著效果。该文综述了近十多年来单味中药防治脂肪肝作用的研究进展情况，发现许多中药是通过调节血脂、保护肝脏免受脂质过氧化损伤来达到防治目的，而像广昆布、海藻等既能调节血脂，又能软坚散结，阻止脂肪肝向肝纤维化、肝硬化发展的药物，更应引起开发研究者和临床应用者的重视。     

Attitudes and beliefs regarding the use of herbs and supplementary medications with COVID-19: A systematic review

Background and aimThere is growing interest in using herbs and supplementary medications to treat and/or prevent COVID-19, evidenced by multiple reports exploring their effectiveness and safety. From a health psychology perspective, the desire to use herbs and supplementary medications to prevent and/or treat COVID-19 is a health behavior which is attributed to attitudes and beliefs. This systematic review critically appraised and synthesized the data from studies investigating these attitudes and beliefs.MethodsEMBASE, PubMed, ScienceDirect, Scopus, Cochrane (library), and WebOfScience were searched from inception to December 13, 2021 for studies investigating attitudes and beliefs on the use of herbs and supplementary medications to treat and/or prevent COVID-19.ResultsA total of 17 articles were identified for inclusion. All except one were of cross-sectional design. Participants across most studies had a positive attitude towards using herbs and supplementary medications. They believed that herbs and supplementary medications were effective and were confident in their value in preventing and/or treating COVID-19 symptoms. The majority of included studies had significant flaws in study design and reporting, including inconsistent definitions of herbs and supplementary medications, a lack of theoretical models and conceptual frameworks underpinning the study of beliefs and attitudes, in addition to methodological issues of robustness affecting the validity and reliability of data.ConclusionThe use of herbs and supplementary medicines to prevent and/or treat COVID-19 could well be driven by a positive attitude stemming from beliefs of effectiveness and safety. There is a need for well-designed studies on attitudes and beliefs that are driven by health behavior theories to permit generalizability of findings and establish more conclusive relationships between beliefs, attitudes and the decision to use herbs and supplementary medications to treat and/or prevent COVID-19.     

建立香港中药不良反应监测系统,发挥中医药在药物滥用防治中的作用

药物滥用是造成药物不良反应的重要原因之一,我国将滥用麻醉药品等称为"吸毒",是形成药物依赖性的主要原因。药物依赖性包括生理依赖和     

浅析脂肪肝治疗中的“肝脾同治”

目前脂肪肝发病呈上升趋势。祖国医学认为人体是一个有机的整体，脂肪肝的发病涉及到多个脏器。笔者认为脂肪肝虽病位在肝，但与脾关系密切，在治疗之时采取“肝脾同治”的方法，往往会取得事半功倍的效果。本文从肝脾生理、病理上的联系，以及机体运化等方面阐释了“肝脾同治”的依据；列举了脂肪肝治疗中“肝脾同治”的常用治法；并就治疗脂肪肝与脾有关的几味常用中药的现代药理研究作了阐述。     

Feitai attenuates bleomycin-induced pulmonary fibrosis in rats

Pulmonary fibrosis is a common consequence of numerous pulmonary diseases. The current therapeutic approaches for this condition are unsatisfactory. Feitai, a composite formula consisting of several herbs, is used in China as a folk remedy for treating patients with pulmonary tuberculosis. In this study, we extensively investigate the effects and mechanisms of Feitai on bleomycin (BLM)-induced pulmonary fibrosis in rats. One hundred and twenty male Sprague-Dawley rats were randomly divided into four groups, referred to as the saline-water, saline-Feitai, BLM-water, and BLM-Feitai groups. Following a single instillation of BLM (5 mg/kg) or saline, rats were orally administered Feitai at a dose of 3 g/kg body weight or sterilized distilled water once daily. Rats were killed at 7, 14, or 28 d post-BLM. Inflammatory cell count, protein concentration, and lactate dehydrogenase activity in bronchoalveolar lavage fluid were measured, and myeloperoxidase activity and lipid peroxide content in lung homogenates were analyzed. Treatment with Feitai inhibited lung fibrotic progression induced by BLM, as indicated by the decrease in lung hydroproline content and lung fibrosis score at 28 d post-BLM. This was accompanied by significant amelioration of BLM-induced body weight loss, lung edema, and inflammatory response during the development of lung injury in the acute phase. The results strongly indicate the beneficial effects of Feitai in protecting against BLM-induced pulmonary fibrosis. Furthermore, the inflammatory response and lipid peroxidation were inhibited by Feitai, suggesting that the effect of this formula on BLM-induced lung injury and fibrosis is associated with antiinflammatory and antioxidant properties.     

海珍玉液对环磷酰胺致大鼠造血功能损伤的预防和治疗作用

海珍玉是由刺参及名贵中药精制而成的海洋保健滋补品，具有促进造血，提高免疫功能，对由化疗引起的白细胞降低亦有预防和治疗作用。对在１６０只大鼠观察了海珍玉液对环磷酰胺中瓣放治疗作用。结果表明，海珍玉液确有提升白细胞，血红蛋白，血小板和网织红细胞的功能，并有促进骨髓造血的作用。     

参芎葡萄糖在治疗肺纤维化中的作用

目的:研究中药参芎葡萄糖在大鼠肺纤维化治疗中的作用.方法:①实验分组:先将健康Wistar大鼠60只随机分两组,对照组20只、模型组40只,若模型成功将模型组再分为模型组(单纯肺纤维化组)、参芎葡萄糖治疗肺纤维化组(简称参芎组),地塞米松治疗肺纤维化组(简称地塞组).②模型制备:采用气管内注射博来霉素(BLM-A5)建...     

小檗碱治疗肺部感染的药理作用研究进展

肺部感染临床常以肺炎形式存出现,治疗核心为抗感染,但多数病原菌对传统药物具有较高的耐药性。小檗碱是从黄连中提取的活性成分,具有多种活性,可通过降低病原菌耐药性,阻止病原菌复制,减轻肺部炎症反应,调节免疫功能,抑制肺纤维化进程,保护血管内皮细胞以治疗肺部感染,减轻肺组织损伤。综述了小檗碱用于肺部感染治疗的药理作用研究进展,为小檗碱临床治疗肺部感染提供依据。